(Q39465499)

12 September 2017

1 reference

title

Acute management of cancer-related hypercalcemia (English)

1 reference

12 September 2017

M A Chisholm

1

1 reference

12 September 2017

A L Mulloy

series ordinal

2

1 reference

12 September 2017

A T Taylor

series ordinal

3

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 May 1996

1 reference

Annals of Pharmacotherapy

12 September 2017

1 reference

12 September 2017

30

1 reference

12 September 2017

507-513

1 reference

12 September 2017

5

1 reference

The hypercalcemia of malignancy: pathogenesis and management

12 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Hypercalcemia in bronchogenic carcinoma. A prospective study of 200 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Pathogenesis of hypercalcaemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Bone involvement in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Drugs for disorders of bone: pharmacological and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Management of acute hypercalcemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Acute treatment of hypercalcemia with furosemide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000514

10.1177/106002809603000514

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference